MAP2K7 and colorectal carcinoma: The FDA-approved drug trametinib is a potent and precise MEK inhibitor that, despite strong preclinical activity, failed to demonstrate significant efficacy in CRC patients (Nalli et al, 2021; Infante et al, 2012).